2. Disease Areas
  3. Digestive System Disease
  4. Liver Disease
  5. Hepatic Fibrosis

Hepatic Fibrosis

Hepatic fibrosis in hepatointestinal schistosomiasis, caused by Schistosoma mansoni, results from egg-induced inflammation in the hepatic periportal region, leading to chronic liver damage, extracellular matrix deposition, and eventual scar formation. This fibrotic process impairs blood flow, contributing to portal hypertension and varices. While most infected individuals do not develop severe fibrosis, 5–10% of the 350 million affected individuals experience significant disease progression. Genetic factors, including loci on chromosome 6q23 harboring IFNGR1 and CTGF genes, play a role in susceptibility to hepatic fibrosis.

Hepatic Fibrosis (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11264
    Cyclic peptide P1-1
    Cyclic peptide P1-1 is a high-potent GPR55 antagonist. Cyclic peptide P1-1 antagonizes GPR55 and suppresses collagen secretion. Cyclic peptide P1-1 reduces ROS production, attenuates ER stress, and inhibits mitochondria-associated Apoptosis. Cyclic peptide P1-1 inhibits the expression of α-SMA and COL1α. Cyclic peptide P1-1 ameliorates CCl4 (HY-Y0298)-induce and MCD-diet-induce acute liver inflammation and fibrosis.
    Cyclic peptide P1-1